A phase 1/2a, dose escalation study of CHR-3996 in combination with tosedostat in subjects with relapsed, refractory multiple myeloma

Authors
Category Primary study
Registry of TrialsEU Clinical Trials Register
Year 2011
This article has no abstract
Epistemonikos ID: bfa9aea870b07ed62af7344e93a58a1b65638de4
First added on: Jan 22, 2025